Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AFT Pharmaceuticals Ltd. ( (AU:AFP) ) just unveiled an update.
AFT Pharmaceuticals has announced a new partnership with Hyloris Pharmaceuticals to advance a novel injectable iron therapy to phase 3 trials, targeting a global market expected to grow to $7.4 billion by 2033. This partnership highlights AFT’s strategic growth in the pharmaceutical industry, with the company expanding its global footprint and expecting record sales in FY25, driven by strong international interest and successful market penetration in regions like China.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals Ltd. is a diversified pharmaceutical company engaged in the development and commercialization of a broad range of medicines. The company focuses on over-the-counter (OTC), hospital, and prescription channels across multiple international markets. AFT has a strong presence in the Australasian iron medicines market with products like Ferro-liquid and FerroTab.
YTD Price Performance: -9.80%
Average Trading Volume: 1,714
Technical Sentiment Signal: Buy
Current Market Cap: A$247.3M
See more data about AFP stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue